Clinical Trial Update: Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating bispecific T-cell redirectors as first-line therapy for transplant-eligible multiple myeloma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Snippet

Sponsor: North Estonia Medical Centre | Conditions: Multiple Myeloma | Phase 2 | Status: RECRUITING